Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised phase III trial of adjuvant chemotherapy after resection of stage III colon adenocarcinoma in patients aged 70 years or older
2014-002517-39Phase 3Active
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Jul 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of oxaliplatin, fluorouracil, folinic acid and capecitabine in colon adenocarcinoma and colon cancer (4 arms), sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoint: Recurrence-free survival at 3 years. Started Jul 2014; status: active.
02
Drugs
oxaliplatinfluorouracilfolinic acidcapecitabine
03
Conditions
colon adenocarcinomacolon cancer
Beyond the preview
Go deeper on 2014-002517-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002517-39.